CLuB’s ambition and focus are on identifying and developing minimally-invasive, cost effective, blood tests to complement or, where possible, replace surgical biopsies for cancer diagnosis and optimal treatment selection. CLuB also uses excised tumours as “avatars” to better understand the specific origin of important components of the liquid biopsy and to test the optimal drug treatment regime for a given patient.

The overall goal of the Hub is to take world-leading research to commercialisation outcomes such as spinouts and licenses. Along with Trinity, University College Dublin (UCD) and RCSI University of Me...